Return to main AirTree site
Investments
5
min read

Building the future of personalised healthcare – Our investment in Human

Published on
July 25, 2022
Enjoy this post?
Subscribe to the AirMail Newsletter
Share

Health Systems in Crisis

When I was 2 years old, my Mum was diagnosed with brain cancer. 2 years after her treatment, it came back with a vengeance as stage 4 brain cancer or Glioblastoma Multiforme (GBM). The average length of survival after a GBM diagnosis is 8 months and less than 1% of patients live longer than 10 years. My Mum was only 33 – my age now – with 3 little kids. I’ll be forever grateful that my Mum was the <1%. She lived for another 22 years after her GBM diagnosis. 

15 years after her treatment ended, she lived in the US where doctors from Stanford took over her annual scans and health checks. They found it almost impossible to believe they had met such a long-term survivor of GBM. They had a local pathologist check her Australian files to ensure she wasn’t misdiagnosed by the Australian doctors 15 years earlier. The pathologist confirmed she did have GBM and she was one of the very few lucky ones to beat it. Although she lived for a long time after her initial diagnosis, no one ever studied her to better understand why she survived when almost everyone else didn’t.

When my first daughter was born, she had a skin condition for which we had to seek specialist medical care. There were various treatment options, each with their own risks, and we were getting conflicting medical advice from specialists. I remember nursing a newborn, searching the internet for academic papers on the side effects of potential treatment options and emailing summaries of pros/cons to my husband and both sets of grandparents as the gravity of making a medical decision for my child weighed so heavily on me as a new parent. 

These are just some of my personal experiences. Healthcare is something that touches us all. There is so much to be thankful for in our modern medical systems. But these systems are also in crisis. Globally 1 in 3 people live with a chronic health condition. 

There are 1 billion health-related Google searches every day. My experience trawling through academic papers is not unique. There must be a better way to give everyone access to personalised healthcare. This belief is what led Georgia and Kate to found Human.

Democratising access to personalised healthcare

Human is a scientific platform that captures what doctors, researchers and patients are learning about the most effective treatments at scale. Human will publish learnings on the most up-to-date discoveries and interventions by doctors and patients to help build personalised and data-driven treatment plans. 

If Human existed when my Mum was alive, she could have contributed to research and influenced the treatments of other GBM patients. If Human existed when my daughter was born, I could have accessed simple data on the success of treatment options and learned from the world’s leading specialists in her condition. 

There are very few health tech companies with missions as ambitious as Human’s. Building the future of personalised healthcare is not going to be easy. But at AirTree we don’t get excited about opportunities because they’re easy. We get excited about big, hard problems that need to be solved. And we back ambitious founders with the resilience to solve them.

Building a world-class team

Georgia and Kate are experienced operators building a world-class product supported by an exceptional team. They are incredibly motivated to reduce the unnecessary suffering from symptoms associated with chronic health conditions and their passion to solve this problem is contagious. 

They’ve inspired world-renowned medical and scientific advisors to support their mission. One, in particular, commented after his first meeting with Georgia and Kate (after a cold outreach) “I see the fire in your bellies. I have no time, but I will give you time”. Another commented after seeing their pitch “I’ve been thinking about every slide in this deck for the last 15 years. This idea could revolutionize medicine”.

“I see the fire in your bellies. I have no time, but I will give you time”.

Georgia and Kate have also inspired a growing team of engineers, operators, product and design leaders, researchers and scientists to help bring their vision to life. One of the first things Georgia and Kate did when they founded Human was to create Human’s company values: Fix Systems, not symptoms; Be clear & be kind; Simpler is smarter; Build impact not empires; Lean into vulnerability; Enjoy the ride! 

I love that they created Human from day 1 with these values top of mind in everything they did. For a young company, it’s clear they have already built an incredibly strong culture, and this will stand them in good stead as they scale their world-class team. If you’re keen to join the Human team - check out their open roles here.

Below is a picture of Georgia and Kate signing the AirTree term sheet for us to lead their seed round. I was on the other side of the camera smiling just as much. I’m proud to back Georgia, Kate and the entire Human team to give everyone access to personalised healthcare and I can’t wait to see their impact over the years to come!

Disclaimer
AirTree Ventures entities listed below are corporate authorised representatives (CAR) of Boutique Capital Pty Ltd (BCPL) AFSL 508011.

CAR has taken all reasonable care in producing all the information contained in the website including but not limited to reports, tables, maps, diagrams and photographs.

However, CAR will not be responsible for loss or damage arising from the use of this information. The contents of this website should not be used as a substitute for detailed investigations or analysis on any issues or questions the reader wishes to have answered.

You may download the information for your own personal use or to inform others about our materials, but you may not reproduce or modify it without our express permission.

To the extent to which this website contains advice it is general advice only and has been prepared by the Company for individuals identified as wholesale investors for the purposes of providing a financial product or financial service, under Section 761G or Section 761GA of the Corporations Act 2001 (Cth).

The information in this website is not intended to be relied upon as advice to investors or potential investors and has been prepared without taking into account personal investment objectives, financial circumstances or particular needs. Recipients of this information are advised to consult their own professional advisers about legal, tax, financial or other matters relevant to the suitability of this information.

Any investment(s) summarised in this website is subject to known and unknown risks, some of which are beyond the control of CAR and their directors, employees, advisers or agents. CAR does not guarantee any particular rate of return or the performance, nor does CAR and its directors personally guarantee the repayment of capital or any particular tax treatment. Past performance is not indicative of future performance.

All investments carry some level of risk, and there is typically a direct relationship between risk and return. We describe what steps we take to mitigate risk (where possible) in the investment documentation, which must be read prior to investing. It is important to note risk cannot be mitigated completely.

Whilst the contents of this website is based on information from sources which CAR considers reliable, its accuracy and completeness cannot be guaranteed. Data is not necessarily audited or independently verified. Any opinions reflect CAR’s judgment at this date and are subject to change. CAR has no obligation to provide revised assessments in the event of changed circumstances. To the extent permitted by law, BCPL, CAR and their directors and employees do not accept any liability for the results of any actions taken or not taken on the basis of information in this website, or for any negligent misstatements, errors or omissions.

AirTree Ventures 2021 Trustco Pty Ltd ACN 652 901 409 CAR Number 1293641, AirTree Ventures Opportunity Fund 2019 Trustco Pty Ltd ACN 633 454 467 CAR Number 1293645, AirTree Ventures Opportunity Fund 2021 Trustco Pty Ltd ACN 652 901 043 CAR Number 1293642, AirTree Ventures Opportunity Fund Trustco Pty Limited ACN 609 594 881 CAR Number 1293643.